WGU D027 OA Exam Advanced Pathopharmacological Foundations Questions and
Verified Answers, 100% Guarantee Pass
Question 1: A 68-year-old female with a history of chronic heart failure with
reduced ejection fraction (HFrEF) presents to the clinic complaining of worsening
dyspnea on exertion and a recent weight gain of 4 pounds over three days. Her
current medication regimen includes lisinopril, carvedilol, and furosemide. The
provider decides to add spironolactone to her regimen. Which of the following
pathophy siologic mechanisms best explains the primary therapeutic benefit of
adding spironolactone in this specific patient population?
A. It provides potent, rapid diuresis by inhibiting the Na+/K+/2Cl- cotransporter in
the thick ascending limb of the loop of Henle.
B. It antagonizes aldosterone receptors, thereby preventing myocardial fibrosis,
reducing ventricular remodeling, and decreasing mortality in HFrEF.
C. It acts as a vasodilator by directly relaxing vascular smooth muscle, thereby
reducing afterload and improving cardiac output.
D. It inhibits the Na+/Cl- cotransporter in the distal convoluted tubule,
providing mild diuresis and reducing preload.
CORRECT ANSWER: B. It antagonizes aldosterone receptors, thereby preventing
myocardial fibrosis, reducing ventricular remodeling, and decreasing mortality in
HFrEF.
Rationale: Spironolactone is an aldosterone antagonist (potassium-sparing
diuretic). In HFrEF, chronic aldosterone elevation leads to sodium retention,
potassium loss, and detrimental myocardial fibrosis and remodeling.
Spironolactone blocks these effects, significantly reducing morbidity and
mortality, which is its primary therapeutic benefit in this population bey ond mild
diuresis.
Question 2: A 55-year-old male with a history of type 2 diabetes mellitus and
hypertension is prescribed a new medication. Two weeks later, he presents with a
persistent, dry, hacking cough that is disrupting his sleep. He denies fever, sputum
production, or shortness of breath. Which of the following medications is most
likely responsible for this adverse effect, and what is the underlying mechanism?
A. Amlodipine; due to peripheral vasodilation causing reflex tachycardia and
cough.
B. Metoprolol; due to beta-2 receptor blockade causing mild
bronchoconstriction.
Page 1 of 235
,C. Lisinopril; due to the accumulation of bradykinin in the respiratory tract.
D. Hydrochlorothiazide; due to electrolyte imbalance causing respiratory muscle
weakness.
CORRECT ANSWER: C. Lisinopril; due to the accumulation of bradykinin in the
respiratory tract.
Rationale: ACE inhibitors (like lisinopril) inhibit the breakdown of bradykinin and
substance P. The accumulation of these inflammatory mediators in the respiratory
tract is the well-documented mechanism behind the characteristic dry , persistent
cough associated with ACE inhibitor therapy .
Question 3: A 72-year-old female is admitted to the hospital with acute
decompensated heart failure and pulmonary edema. She is hypoxic and
tachypneic. The healthcare provider orders intravenous furosemide. Which of the
following assessments is the most critical for the nurse to monitor immediately
following the administration of this medication to evaluate its therapeutic efficacy
?
A. Daily weight and strict intake and output measurements.
B. Serum potassium and magnesium levels.
C. Respiratory rate, oxygen saturation, and auscultation of lung sounds.
D. Blood pressure and heart rate.
CORRECT ANSWER: C. Respiratory rate, oxygen saturation, and auscultation of lung
sounds.
Rationale: While all options are important, the immediate therapeutic goal of IV
furosemide in acute pulmonary edema is to reduce fluid overload in the lungs.
Therefore, monitoring respiratory rate, oxygen saturation, and lung sounds
provides the most direct and immediate assessment of the drug's efficacy in
resolving the life-threatening pulmonary edema.
Question 4: A 45-year-old male with a history of gout presents to the clinic with an
acute, exquisitely painful, red, and swollen first metatarsophalangeal (MTP) joint.
He has no history of renal impairment or peptic ulcer disease. Which of the
following pharmacologic interventions is considered the first-line treatment for
this acute gout flare, and what is its primary mechanism of action?
A. Allopurinol; inhibits xanthine oxidase to decrease uric acid production.
Page 2 of 235
,B. Colchicine; inhibits microtubule poly merization, impairing leukocyte
migration and phagocytosis.
C. Probenecid; inhibits renal tubular reabsorption of uric acid to increase its
excretion.
D. Febuxostat; selectively inhibits xanthine oxidase to lower serum uric acid
levels.
CORRECT ANSWER: B. Colchicine; inhibits microtubule poly merization,
impairing leukocyte migration and phagocytosis.
Rationale: For an acute gout flare, NSAIDs, colchicine, or corticosteroids are
first-line. Colchicine works by binding to tubulin, inhibiting microtubule poly
merization, which impairs the migration and phagocytic activity of
leukocytes to the inflamed joint, thereby reducing inflammation. Allopurinol and
febuxostat are for chronic management, not acute flares.
Question 5: A 60-year-old female with a history of atrial fibrillation is taking
warfarin for stroke prophy laxis. She presents to the clinic with a minor laceration
on her arm that will not stop bleeding. Her INR is found to be 4.8. She is
hemodynamically stable and has no signs of major internal bleeding. What is the
most ap propriate initial pharmacologic management for this patient?
A. Administer intravenous vitamin K and fresh frozen plasma (FFP) immediately.
B. Hold the next 1 to 2 doses of warfarin and monitor the INR closely.
C. Administer oral vitamin K (1 to 2.5 mg) and hold the warfarin dose.
D. Continue the current warfarin dose and ap ply topical thrombin to the
laceration.
CORRECT ANSWER: C. Administer oral vitamin K (1 to 2.5 mg) and hold the
warfarin dose.
Rationale: For an INR between 4.5 and 10 without significant bleeding, the
guidelines recommend holding 1 to 2 doses of warfarin and optionally
administering a low dose of oral vitamin K to gently reverse the anticoagulation. IV
vitamin K and FFP are reserved for life-threatening or major bleeding.
Question 6: A 30-year-old female is diagnosed with a severe urinary tract infection
(UTI) caused by Escherichia coli. The provider prescribes ciprofloxacin. The patient
asks the nurse why she must avoid taking this medication at the
Page 3 of 235
, same time as her daily calcium and iron sup plements. What is the most accurate
pathopharmacologic explanation the nurse should provide?
A. Calcium and iron increase the gastric pH, which destroys the ciprofloxacin
molecule before it can be absorbed.
B. Ciprofloxacin binds to the divalent and trivalent cations (calcium, iron,
magnesium) in the gastrointestinal tract, forming insoluble chelates that
drastically reduce the antibiotic's absorption.
C. Calcium and iron induce hepatic cytochrome P450 enzymes, leading to rapid
metabolism and subtherapeutic levels of ciprofloxacin.
D. Ciprofloxacin and these sup plements compete for the same active transport
receptors in the renal tubules, causing toxic accumulation of the antibiotic.
CORRECT ANSWER: B. Ciprofloxacin binds to the divalent and trivalent cations
(calcium, iron, magnesium) in the gastrointestinal tract, forming insoluble chelates
that drastically reduce the antibiotic's absorption.
Rationale: Fluoroquinolones like ciprofloxacin readily chelate with divalent and
trivalent cations (such as Ca2+, Fe2+/3+, Mg2+, and Al3+) found in antacids, dairy,
and mineral sup plements. This forms an insoluble complex in the GI tract, severely
impairing the oral bioavailability of the antibiotic.
Question 7: A 50-year-old male with a history of chronic obstructive pulmonary
disease (COPD) is prescribed a new inhaler regimen consisting of fluticasone (an
inhaled corticosteroid) and salmeterol (a long-acting beta-2 agonist). The patient
asks why he cannot just use the salmeterol inhaler alone when he feels short of
breath. What is the most ap propriate rationale the nurse should provide?
A. Salmeterol alone is not ap proved by the FDA for any respiratory conditions.
B. Using a long-acting beta-2 agonist (LABA) without an inhaled corticosteroid in
asthma or COPD increases the risk of severe asthma exacerbations and asthma-
related death.
C. Salmeterol causes severe systemic immunosup pression, which must be
counteracted by the corticosteroid.
D. Fluticasone is required to dilate the airways, while salmeterol is only used to
reduce inflammation.
CORRECT ANSWER: B. Using a long-acting beta-2 agonist (LABA) without an inhaled
corticosteroid in asthma or COPD increases the risk of severe asthma
Page 4 of 235
Verified Answers, 100% Guarantee Pass
Question 1: A 68-year-old female with a history of chronic heart failure with
reduced ejection fraction (HFrEF) presents to the clinic complaining of worsening
dyspnea on exertion and a recent weight gain of 4 pounds over three days. Her
current medication regimen includes lisinopril, carvedilol, and furosemide. The
provider decides to add spironolactone to her regimen. Which of the following
pathophy siologic mechanisms best explains the primary therapeutic benefit of
adding spironolactone in this specific patient population?
A. It provides potent, rapid diuresis by inhibiting the Na+/K+/2Cl- cotransporter in
the thick ascending limb of the loop of Henle.
B. It antagonizes aldosterone receptors, thereby preventing myocardial fibrosis,
reducing ventricular remodeling, and decreasing mortality in HFrEF.
C. It acts as a vasodilator by directly relaxing vascular smooth muscle, thereby
reducing afterload and improving cardiac output.
D. It inhibits the Na+/Cl- cotransporter in the distal convoluted tubule,
providing mild diuresis and reducing preload.
CORRECT ANSWER: B. It antagonizes aldosterone receptors, thereby preventing
myocardial fibrosis, reducing ventricular remodeling, and decreasing mortality in
HFrEF.
Rationale: Spironolactone is an aldosterone antagonist (potassium-sparing
diuretic). In HFrEF, chronic aldosterone elevation leads to sodium retention,
potassium loss, and detrimental myocardial fibrosis and remodeling.
Spironolactone blocks these effects, significantly reducing morbidity and
mortality, which is its primary therapeutic benefit in this population bey ond mild
diuresis.
Question 2: A 55-year-old male with a history of type 2 diabetes mellitus and
hypertension is prescribed a new medication. Two weeks later, he presents with a
persistent, dry, hacking cough that is disrupting his sleep. He denies fever, sputum
production, or shortness of breath. Which of the following medications is most
likely responsible for this adverse effect, and what is the underlying mechanism?
A. Amlodipine; due to peripheral vasodilation causing reflex tachycardia and
cough.
B. Metoprolol; due to beta-2 receptor blockade causing mild
bronchoconstriction.
Page 1 of 235
,C. Lisinopril; due to the accumulation of bradykinin in the respiratory tract.
D. Hydrochlorothiazide; due to electrolyte imbalance causing respiratory muscle
weakness.
CORRECT ANSWER: C. Lisinopril; due to the accumulation of bradykinin in the
respiratory tract.
Rationale: ACE inhibitors (like lisinopril) inhibit the breakdown of bradykinin and
substance P. The accumulation of these inflammatory mediators in the respiratory
tract is the well-documented mechanism behind the characteristic dry , persistent
cough associated with ACE inhibitor therapy .
Question 3: A 72-year-old female is admitted to the hospital with acute
decompensated heart failure and pulmonary edema. She is hypoxic and
tachypneic. The healthcare provider orders intravenous furosemide. Which of the
following assessments is the most critical for the nurse to monitor immediately
following the administration of this medication to evaluate its therapeutic efficacy
?
A. Daily weight and strict intake and output measurements.
B. Serum potassium and magnesium levels.
C. Respiratory rate, oxygen saturation, and auscultation of lung sounds.
D. Blood pressure and heart rate.
CORRECT ANSWER: C. Respiratory rate, oxygen saturation, and auscultation of lung
sounds.
Rationale: While all options are important, the immediate therapeutic goal of IV
furosemide in acute pulmonary edema is to reduce fluid overload in the lungs.
Therefore, monitoring respiratory rate, oxygen saturation, and lung sounds
provides the most direct and immediate assessment of the drug's efficacy in
resolving the life-threatening pulmonary edema.
Question 4: A 45-year-old male with a history of gout presents to the clinic with an
acute, exquisitely painful, red, and swollen first metatarsophalangeal (MTP) joint.
He has no history of renal impairment or peptic ulcer disease. Which of the
following pharmacologic interventions is considered the first-line treatment for
this acute gout flare, and what is its primary mechanism of action?
A. Allopurinol; inhibits xanthine oxidase to decrease uric acid production.
Page 2 of 235
,B. Colchicine; inhibits microtubule poly merization, impairing leukocyte
migration and phagocytosis.
C. Probenecid; inhibits renal tubular reabsorption of uric acid to increase its
excretion.
D. Febuxostat; selectively inhibits xanthine oxidase to lower serum uric acid
levels.
CORRECT ANSWER: B. Colchicine; inhibits microtubule poly merization,
impairing leukocyte migration and phagocytosis.
Rationale: For an acute gout flare, NSAIDs, colchicine, or corticosteroids are
first-line. Colchicine works by binding to tubulin, inhibiting microtubule poly
merization, which impairs the migration and phagocytic activity of
leukocytes to the inflamed joint, thereby reducing inflammation. Allopurinol and
febuxostat are for chronic management, not acute flares.
Question 5: A 60-year-old female with a history of atrial fibrillation is taking
warfarin for stroke prophy laxis. She presents to the clinic with a minor laceration
on her arm that will not stop bleeding. Her INR is found to be 4.8. She is
hemodynamically stable and has no signs of major internal bleeding. What is the
most ap propriate initial pharmacologic management for this patient?
A. Administer intravenous vitamin K and fresh frozen plasma (FFP) immediately.
B. Hold the next 1 to 2 doses of warfarin and monitor the INR closely.
C. Administer oral vitamin K (1 to 2.5 mg) and hold the warfarin dose.
D. Continue the current warfarin dose and ap ply topical thrombin to the
laceration.
CORRECT ANSWER: C. Administer oral vitamin K (1 to 2.5 mg) and hold the
warfarin dose.
Rationale: For an INR between 4.5 and 10 without significant bleeding, the
guidelines recommend holding 1 to 2 doses of warfarin and optionally
administering a low dose of oral vitamin K to gently reverse the anticoagulation. IV
vitamin K and FFP are reserved for life-threatening or major bleeding.
Question 6: A 30-year-old female is diagnosed with a severe urinary tract infection
(UTI) caused by Escherichia coli. The provider prescribes ciprofloxacin. The patient
asks the nurse why she must avoid taking this medication at the
Page 3 of 235
, same time as her daily calcium and iron sup plements. What is the most accurate
pathopharmacologic explanation the nurse should provide?
A. Calcium and iron increase the gastric pH, which destroys the ciprofloxacin
molecule before it can be absorbed.
B. Ciprofloxacin binds to the divalent and trivalent cations (calcium, iron,
magnesium) in the gastrointestinal tract, forming insoluble chelates that
drastically reduce the antibiotic's absorption.
C. Calcium and iron induce hepatic cytochrome P450 enzymes, leading to rapid
metabolism and subtherapeutic levels of ciprofloxacin.
D. Ciprofloxacin and these sup plements compete for the same active transport
receptors in the renal tubules, causing toxic accumulation of the antibiotic.
CORRECT ANSWER: B. Ciprofloxacin binds to the divalent and trivalent cations
(calcium, iron, magnesium) in the gastrointestinal tract, forming insoluble chelates
that drastically reduce the antibiotic's absorption.
Rationale: Fluoroquinolones like ciprofloxacin readily chelate with divalent and
trivalent cations (such as Ca2+, Fe2+/3+, Mg2+, and Al3+) found in antacids, dairy,
and mineral sup plements. This forms an insoluble complex in the GI tract, severely
impairing the oral bioavailability of the antibiotic.
Question 7: A 50-year-old male with a history of chronic obstructive pulmonary
disease (COPD) is prescribed a new inhaler regimen consisting of fluticasone (an
inhaled corticosteroid) and salmeterol (a long-acting beta-2 agonist). The patient
asks why he cannot just use the salmeterol inhaler alone when he feels short of
breath. What is the most ap propriate rationale the nurse should provide?
A. Salmeterol alone is not ap proved by the FDA for any respiratory conditions.
B. Using a long-acting beta-2 agonist (LABA) without an inhaled corticosteroid in
asthma or COPD increases the risk of severe asthma exacerbations and asthma-
related death.
C. Salmeterol causes severe systemic immunosup pression, which must be
counteracted by the corticosteroid.
D. Fluticasone is required to dilate the airways, while salmeterol is only used to
reduce inflammation.
CORRECT ANSWER: B. Using a long-acting beta-2 agonist (LABA) without an inhaled
corticosteroid in asthma or COPD increases the risk of severe asthma
Page 4 of 235
